Homology Medicines, Inc. (0T6G.L)
USD 1.87
(-4.64%)
USD 1.87
(-4.64%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -48.25 Million USD | 63.79% |
| 2022 | -133.28 Million USD | -38.91% |
| 2021 | -95.94 Million USD | 26.34% |
| 2020 | -130.26 Million USD | -18.48% |
| 2019 | -109.94 Million USD | -83.46% |
| 2018 | -59.92 Million USD | -102.06% |
| 2017 | -29.65 Million USD | -196.57% |
| 2016 | -10 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -14.84 Million USD | -57.67% |
| 2024 Q2 | -17.91 Million USD | -20.72% |
| 2023 Q3 | -24.36 Million USD | 20.95% |
| 2023 Q4 | -9.41 Million USD | 61.36% |
| 2023 Q1 | -27.51 Million USD | 20.24% |
| 2023 FY | -92.1 Million USD | 30.9% |
| 2023 Q2 | -30.81 Million USD | -12.01% |
| 2022 Q1 | -37.61 Million USD | -11.88% |
| 2022 Q4 | -34.49 Million USD | -4.97% |
| 2022 Q2 | -28.3 Million USD | 24.75% |
| 2022 Q3 | -32.86 Million USD | -16.09% |
| 2022 FY | -133.28 Million USD | -38.91% |
| 2021 Q2 | -30.55 Million USD | -2649.95% |
| 2021 FY | -95.94 Million USD | 26.34% |
| 2021 Q1 | -1.11 Million USD | 96.27% |
| 2021 Q4 | -33.62 Million USD | -9.67% |
| 2021 Q3 | -30.66 Million USD | -0.36% |
| 2020 Q4 | -29.8 Million USD | -5.41% |
| 2020 FY | -130.26 Million USD | -18.48% |
| 2020 Q2 | -35.69 Million USD | 2.18% |
| 2020 Q1 | -36.49 Million USD | -42.78% |
| 2020 Q3 | -28.27 Million USD | 20.8% |
| 2019 Q3 | -31.28 Million USD | -11.85% |
| 2019 Q1 | -25.12 Million USD | -24.54% |
| 2019 FY | -109.94 Million USD | -83.46% |
| 2019 Q4 | -25.55 Million USD | 18.31% |
| 2019 Q2 | -27.97 Million USD | -11.34% |
| 2018 Q2 | -13.42 Million USD | -25.49% |
| 2018 Q4 | -20.17 Million USD | -29.02% |
| 2018 FY | -59.92 Million USD | -102.06% |
| 2018 Q1 | -10.69 Million USD | 12.77% |
| 2018 Q3 | -15.63 Million USD | -16.49% |
| 2017 Q1 | -4.69 Million USD | 0.0% |
| 2017 FY | -29.65 Million USD | -196.57% |
| 2017 Q3 | -6.66 Million USD | -10.37% |
| 2017 Q4 | -12.26 Million USD | -83.99% |
| 2017 Q2 | -6.03 Million USD | -28.71% |
| 2016 FY | -10 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.704% |
| Dynavax Technologies Corporation | -37.02 Million USD | -30.32% |
| Illumina, Inc. | -1.06 Billion USD | 95.486% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 102.441% |
| Biogen Inc. | 1.29 Billion USD | 103.721% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 89.523% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 104.438% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 81.983% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -815.828% |
| Waters Corporation | 817.67 Million USD | 105.901% |
| Perrigo Company plc | 151.9 Million USD | 131.768% |
| uniQure N.V. | -282.87 Million USD | 82.941% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 87.674% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 34.342% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 82.517% |
| bluebird bio, Inc. | -244.26 Million USD | 80.245% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 60.282% |
| Imunon, Inc. | -21.03 Million USD | -129.453% |
| Myriad Genetics, Inc. | -123.7 Million USD | 60.99% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 119.233% |
| Nektar Therapeutics | -137.42 Million USD | 64.886% |
| Editas Medicine, Inc. | -169.18 Million USD | 71.477% |
| Verastem, Inc. | -92.08 Million USD | 47.597% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.657% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -7.049% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 56.376% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -8.033% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 124.817% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 82.389% |
| Evolus, Inc. | -49.23 Million USD | 1.986% |
| Adicet Bio, Inc. | -152.03 Million USD | 68.261% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 50.435% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 101.192% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 68.98% |
| FibroGen, Inc. | -281.81 Million USD | 82.877% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 103.574% |
| OPKO Health, Inc. | -157.02 Million USD | 69.268% |
| Geron Corporation | -193.94 Million USD | 75.119% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 82.899% |
| Exelixis, Inc. | 170.88 Million USD | 128.238% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 52.141% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 13.453% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 90.635% |
| Zoetis Inc. | 3.06 Billion USD | 101.572% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 79.185% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -0.114% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.12% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -23.247% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 86.358% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 144.98% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 114.295% |
| Blueprint Medicines Corporation | -486.27 Million USD | 90.077% |
| Insmed Incorporated | -709.62 Million USD | 93.2% |
| TG Therapeutics, Inc. | 20.63 Million USD | 333.873% |
| Incyte Corporation | 620.52 Million USD | 107.776% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 93.357% |